Dogwood Flags Going Concern, Cash Only Through Q4 2026
DWTX sits 55% above its 52-week low of $1.28 on light trading volume (0.1× avg).
Summary
Dogwood Therapeutics reported a Q2 net loss of $11.5 million and disclosed a going concern warning, with cash only funding operations into Q4 2026.
Key Events · Earnings and Guidance · DWTX
-
Going Concern Warning
Management states cash of $9.6 million is not sufficient to fund operations for at least 12 months, and substantial doubt exists about the company's ability to continue as a going concern.
-
Cash Runway Through Q4 2026
The company expects cash to fund operations only into the fourth quarter of 2026, requiring additional financing beyond that point.
-
Q2 Net Loss of $11.5M
Net loss was $11.5 million, or $0.34 per share, driven by a $9.2 million IPR&D impairment partially offset by a $2.5 million deferred tax benefit.
-
PRIDCor First Payment
In July 2026, PRIDCor broke escrow and Dogwood received its first $100,000 payment under the license agreement, with $87,750 payable to CVR holders.
Analysis · DWTX · Life Sciences
The 10-Q confirms the Q2 net loss of $11.5 million already reported, but the critical new disclosure is the going concern statement: cash of $9.6 million is insufficient to fund operations for 12 months, and the company must raise capital beyond Q4 2026. This is a first-time formal going concern warning, which materially raises the risk of dilution or failure. The subsequent event of a $100,000 PRIDCor payment is minor but shows the license agreement is beginning to generate cash.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DWTX was trading at $1.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.9M. The 52-week trading range was $1.28 to $9.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.